Hematology
From the Journals
Coagulopathy outbreak underscores danger of synthetic cannabinoids
Four patients died after developing spontaneous intracranial bleeding.
Conference Coverage
Rivaroxaban bonus: Early unmasking of occult GI cancers
MUNICH – Secondary analysis of COMPASS trial hits pay dirt.
From the Journals
Hormonal contraceptive use linked to leukemia risk in offspring
Maternal use of hormonal contraceptives close to pregnancy is associated with a small increase in the risk of nonlymphoid leukemia in offspring....
Latest News
Caplacizumab approved in Europe to treat aTTP
The drug is under priority review by the U.S. Food and Drug Administration.
From the Journals
Avatrombopag cut procedure-related transfusions in patients with thrombocytopenia, chronic liver disease
In both trials, the primary endpoint met a high degree of statistical significance.
Latest News
Emicizumab beats factor VIII prophylaxis by a wide margin
In the HAVEN 3 trial, patients with hemophilia A without inhibitors had a significant reduction in bleeding events and no thrombotic events.
From the Journals
Cervical cancer screening recommendations vary by age and risk
Conference Coverage
A new, simple, inexpensive DVT diagnostic aid
NEW ORLEANS – The CBC holds info that outperforms the D-dimer test.
News
FDA warns against azithromycin in blood or lymph node cancers
Azithromycin can lead to relapse and death when used to prevent an inflammatory lung condition in patients with blood or lymph node cancers who...
Feature
In Ghana, SCD research is meeting patients on home turf
The West African nation stands ready to solve the geographic mismatch between research capacity and patient population.
News
FDA approves Nivestym, second biosimilar to Neupogen
Nivestym (filgrastim-aafi), a biosimilar to Neupogen (filgrastim) was approved July 20 by the FDA.